日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

伊克珠单抗（无论是否联合甲氨蝶呤）可改善银屑病关节炎的体征和症状：Spirit-P1 和 Spirit-P2 研究的第 52 周结果

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-020-02388-5
Combe, Bernard; Tsai, Tsen-Fang; Huffstutter, J Eugene; Sprabery, Aubrey Trevelin; Lin, Chen-Yen; Park, So Young; Kronbergs, Andris; Hufford, Matthew M; Nash, Peter
关节炎
银屑病
发表日期：2021
文献求助 收藏

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

ARRIVE试验：在接受抗肿瘤坏死因子治疗后停药或直接换用阿巴西普治疗的类风湿性关节炎患者中，阿巴西普6个月的安全性和有效性评估

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2008.099218
Schiff, M; Pritchard, C; Huffstutter, J E; Rodriguez-Valverde, V; Durez, P; Zhou, X; Li, T; Bahrt, K; Kelly, S; Le Bars, M; Genovese, M C
关节炎
肿瘤
肿瘤免疫
发表日期：2009
文献求助 收藏